ArticleMolecular and cellular biochemistry2018
Adiponectin and colon cancer: evidence for inhibitory effects on viability and migration of human colorectal cell lines.
Article in Molecular and cellular biochemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- AdipoRon, an Adiponectin Receptor Agonist, Promotes Intestinal Epithelial Differentiation in Caco-2 Colorectal Adenocarcinoma Cells.Biomedicines · 2026Article
- AdipoRon Modulation of the Invasive Potential of Prostate Cancer Cells Is Dependent on Their EMT-Related Phenotype.Biomedicines · 2026Article
- The adipokines in oral cancer pathogenesis and its potential as a new therapeutic approach.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Unravelling the Adiponectin Hallmark and Exploring the Therapeutic Potential of Its Receptor Agonists in Cancer Metabolic Reprogramming.Biomolecules · 2025Review
- Obesity-cancer axis crosstalk: Molecular insights and therapeutic approaches.Acta pharmaceutica Sinica. B · 2025Review
- The role of adipogenic niche resident cells in colorectal cancer progression in relation to obesity.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Article
- Adipokines and epithelial-mesenchymal transition (EMT) in cancer.Molecular and cellular biochemistry · 2023Review
- Multi-Faceted Role of Cancer-Associated Adipocytes in Colorectal Cancer.Biomedicines · 2023Review
- Role of Leptin and Adiponectin in Carcinogenesis.Cancers · 2023Review
- Obesity hormones and itaconate mediating inflammation in human colon cancer cells - Another lead to early-onset colon cancer?Heliyon · 2023Article
- Deep Learning Analysis of the Adipose Tissue and the Prediction of Prognosis in Colorectal Cancer.Frontiers in nutrition · 2022Article
- microRNA-377-3p downregulates the oncosuppressor T-cadherin in colorectal adenocarcinoma cells.Cell biology international · 2021Article
- The bifurcated role of adiponectin in colorectal cancer.Life sciences · 2021Review
- Adiponectin and leptin exert antagonizing effects on proliferation and motility of papillary thyroid cancer cell lines.Journal of physiology and biochemistry · 2021Article
- Tumor Metabolic Reprogramming by Adipokines as a Critical Driver of Obesity-Associated Cancer Progression.International journal of molecular sciences · 2021Review
- Targeting Adipokines in Obesity-Related Tumors.Frontiers in oncology · 2021Review
- Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression.International journal of molecular sciences · 2020Review
- Adipocytes protect fibroblasts from radiation-induced damage by adiponectin secretion.Scientific reports · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adiponectin (Acrp30) is an adipokine widely studied for its beneficial metabolic and anti-inflammatory properties. Colorectal cancer is among the most common cancers worldwide. The aim of present study was to explore the effects of Acrp30 on both CaCo-2 and HCT116 colorectal cancer cells in terms of viability, oxidative stress, and apoptosis. In addition, since colorectal cancer represents a typical inflammation-related cancer, we investigated whether Acrp30 treatment modifies the migration and the expression of crucial proteins in the EMT transition. Finally, we analyzed the expression of cytokines in CaCo-2 cells. We found that Acrp30 reduces the survival rate of both CaCo-2 and HCT116 cells through induction of apoptosis and oxidative stress already after 24 h of treatment. In addition, wound-healing assay indicated that Acrp30 exposure statistically inhibits CaCo-2 and HCT116 cell migration. Western blot analysis performed on E-cadherin and vimentin, two EMT crucial markers in carcinogenesis, indicated that Acrp30 does not influence EMT transition. Finally, we found a reduction of mRNA levels corresponding to the anti-inflammatory IL-10 cytokine together with an increase of the pro-inflammatory IL-6 and IL-8 cytokines. This study provides new insight into Acrp30 molecular effects on colorectal cancer cells. Indeed, even if further studies are necessary to clarify the precise role of Acrp30 in colorectal cancer, our data strongly suggest that Acrp30 negatively regulates cell survival and migration in association with induction of oxidative stress and regulation of cytokines expression in both CaCo-2 and HCT116 colorectal cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.